Tag Archives: HHS

Pharma Gains from Rule On Health Insurance Benefits

By Jill Wechsler | Published: November 28, 2012

Recent change likely to boost drug coverage by plans, but with variation in formularies. Health plans offering coverage to individuals and small companies are more likely to cover multiple drugs in each class or category under revised regulations proposed by the Department of Health and Human Services in November. A key change in rules to implement [...]

Posted in Legal, Regulatory, Strategy, healthcare | Also tagged Affordable Care Act, essential health benefits, Medicare Part D, PBMs | Leave a comment

The Bare Essentials: One Way of Looking at HHS's Latest Pitch

By Clark Herman | Published: November 27, 2012

Last Tuesday, HHS proposed regulations that, most notably, shed light on one of ACA’s centerpieces: gutting the insurance industry’s ability to limit coverage based on pre-existing conditions, and establishing new criteria for evaluating eligibility.

Posted in Regulatory, healthcare | Also tagged ACA, EHB, essential health benefits, health insurance | Leave a comment

With the Election Decided, It's Full Speed Ahead on ObamaCare

By Guest Blogger | Published: November 7, 2012

by Tom Norton With the Presidential election decided and President Obama the clear winner, it’s time for Pharma to get down to business on the implementation of ObamaCare. Here are some of the key actions to anticipate between now and January 1, 2013.

Posted in FDA, Legal, Regulatory, Strategy, healthcare | Also tagged Affordable Care Act, Medicare, Obamacare, Presidential election, Regulatory, US election | 3 Comments

Taxpayers and Embryonic Stem Cell Research

By Ben Comer | Published: August 29, 2012

Last Friday, an appellate court upheld an earlier judgment allowing government to fund embryonic stem cell research for the development of new therapies. Biotechs and advocacy groups cheered the decision but uncertainty remains, in large part due to the possibility of a Romney administration in the White House.

Posted in Biotech, Legal, R&D, Regulatory, Strategy, Technology | Also tagged Embryonic stem cell, Kathleen Sebelius, NIH, Regulatory Guidelines, Regulatory Science, Stem cell, Stem Cell Research | Leave a comment

Comply or Die: Introducing GSK's New Corporate Integrity Agreement

By Ben Comer | Published: July 6, 2012

Big pharma talks a lot about the changing business model and placing a new emphasis on patients, but the fact remains that quantity of medicines sold, not quality of care provided, is how to get paid (and how to keep investors happy). Despite its egalitarian trappings, the healthcare “ecosystem” is still dominated by the [...]